Teva Challenges Novartis SPC For High Blood Pressure Drug
Teva has asked a London judge to nix a supplementary protection certificate extending protection for a Novartis hypertension treatment, arguing that the underlying patent has always been invalid as it looks...To view the full article, register now.
Already a subscriber? Click here to view full article